Austedo (Deutetrabenazine): The 2031-2038 Generic Opportunity Window

Teva Pharmaceutical Industries Ltd.'s blockbuster vesicular monoamine transporter 2 (VMAT2) inhibitor Austedo and Austedo XR (deutetrabenazine oral tablets, NDA 208082 and NDA 216773) generated $1.225 billion in full-year 2023 global revenues, surging 34% to $1.642 billion in 2024 and exceeding $2.26 billion in 2025, with U.S. sales accounting for more than 95% of franchise revenue. Indicated for chorea associated with Huntington's disease and tardive dyskinesia in adult patients, Austedo maintains an unchallenged 100% brand-only monopoly in the United States today, with zero generic versions commercially approved or selling. Core composition-of-matter and substance patent US 8,524,733 expires on April 3, 2031, incorporating statutory Patent Term Extension granted under 35 U.S.C. 156. Secondary method-of-use and extended-release formulation patents extend Orange Book protection through 2038 to 2041. In May 2022, Teva resolved Hatch-Waxman Paragraph IV patent litigation with leading generic challengers--prominently including Indian pharmaceutical powerhouses Lupin Limited and Aurobindo Pharma--licensing generic entry into the U.S. market in April 2033 (or earlier under standard acceleration clauses), defining the crucial 2031-2038 commercial generic opportunity window.